ANIXA BIOSCIENCES, INC. Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31)
ANIXA BIOSCIENCES, INC. (ANIX) reported Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) of $1.46 million for the 9-month period ending 2014-07-31, per its 10-Q filed 2014-09-15.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings · last filed 2014-09-15
- ANIXA BIOSCIENCES, INC. fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2014-07-31 was -$850.00K.
- ANIXA BIOSCIENCES, INC. fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2014-04-30 was $990.70K.
- ANIXA BIOSCIENCES, INC. fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2014-01-31 was $1.32M.
- ANIXA BIOSCIENCES, INC. fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for the quarter ending 2013-10-31 was -$955.19K.
- ANIXA BIOSCIENCES, INC. fair value, measured on recurring basis, gain (loss) included in earnings (deprecated 2019-01-31) for fiscal 2013 was -$475.19K.
| Period end | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 3 month | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 6 month | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 9 month | Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings (Deprecated 2019-01-31) 12 month |
|---|---|---|---|---|
| 2014-07-31 | -$850.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15 | $140.70K derived: sum of 2 quarters · filed 2014-09-15 | $1.46M 10-Q · filed 2014-09-15 | $505.51K derived: sum of 4 quarters · filed 2014-09-15 |
| 2014-04-30 | $990.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-06-16 | $2.31M 10-Q · filed 2014-06-16 | $1.36M derived: sum of 3 quarters · filed 2014-06-16 | |
| 2014-01-31 | $1.32M 10-Q · filed 2014-03-17 | $364.81K derived: sum of 2 quarters · filed 2014-03-17 | ||
| 2013-10-31 | -$955.19K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2014-01-17 | -$475.19K 10-K/A · filed 2014-01-17 | ||
| 2013-07-31 | $480.00K 10-Q/A · filed 2013-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |